Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1001P is a pseudogene copy of the U6 small nuclear RNA (snRNA) gene, which in its functional form is a key non-coding RNA component of the spliceosome, the complex responsible for pre-mRNA splicing in the nucleus of eukaryotic cells[1][3]. Pseudogenes like RNU6-1001P are defective genomic copies that cannot produce functional snRNA. They are typically generated by L1-mediated retrotransposition, a process where RNA intermediates are reverse transcribed and inserted elsewhere in the genome, often marked by features such as absence of introns and poly(A) tails[2][4]. Such pseudogenes are not recognized as therapeutic targets and do not encode proteins or actively participate in spliceosomal or cellular processes[2][4]. Presence of this pseudogene in the genome reflects evolutionary history and retrotransposition activity but has no direct role in cellular function or disease association currently. There are no known drugs, biomarkers, mechanisms of action, or safety concerns related to RNU6-1001P[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 1001, pseudogene (RNU6-1001P).